Currentblue cross blue shield - south dakotaPolicy 07.01.86

Cryoablation, Radiofrequency Ablation and Laser Ablation for Treatment of Chronic Rhinitis

This policy governs coverage determinations for cryoablation, radiofrequency ablation, and laser ablation to treat chronic (allergic or nonallergic) rhinitis, focusing on patients refractory to medical management and affecting providers and members of the payer.

Policy Summary

Payerblue cross blue shield - south dakota

PolicyCryoablation, Radiofrequency Ablation and Laser Ablation for Treatment of Chronic Rhinitis

Policy CodePolicy 07.01.86

Change TypePolicy renewal

Effective Date

Next Review Date

Key ActionVerify and document that the adult patient has chronic rhinitis refractory to adequate medical therapy before requesting coverage or prior authorization.

SourceLink

POLICY UPDATE CHANGES

No material clinical or coverage changes in this revision.

3procedures reviewed

2CPT codes listed

10-22%persistent patients (%)

1RCTs identified

0laser FDA-cleared

Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.

Coverage Criteria and Evidence Summary

Investigational — all modalities

Covered stance and criteria

Investigational stance for each modality: Cryoablation, radiofrequency ablation, and laser ablation for chronic rhinitis (allergic or nonallergic) are considered investigational because evidence is insufficient to demonstrate improvement in net health outcome.

Policy explicitly states investigational for all three modalities.

Study-based eligibility criteria

Covered when ALL of the following are met in study eligibility frameworks

Adult patients: Patient is an adult (age ≥18 years).age >= 18

Supported by population definition in the evidence base (adults).

Diagnosis of chronic allergic or nonallergic rhinitis (symptomatic inflammation of the nasal cavity/paranasal sinuses).chronic symptoms >3 months

Chronic rhinitis usually defined as symptoms >3 months despite medical therapy.

Refractory to medical management: Symptoms refractory to medical management as documented in the medical record (examples in studies: inadequate relief after ≥4 weeks of intranasal steroids or failure of medical therapy for ≥3 months).documented failure of medical therapy (eg, ≥4 weeks topical nasal steroid or ≥3 months of therapy)

Definitions of refractory varied across studies; documentation expected.

Absence of anatomic or safety exclusions: No anatomic limitation preventing access to the posterior nasal cavity, no active nasal/sinus infection, not pregnant, no nasopharyngeal malignancy, no coagulopathy or conflicting systemic condition as described in study exclusions.clinical exclusion checklist

Reflects exclusion criteria used in nonrandomized studies and trial reports.

Evidence and applicability criteria

Evidence supports symptomatic improvement in trials but key applicability conditions are unclear; coverage conclusions hinge on documented refractory status and trial limitations.

Evidence summary conditions

Study limitations: Major limitations include unclear refractory status of RCT populations, open-label single-arm designs, high loss to follow-up, and inconsistent prespecification of clinically important differences.
These limitations preclude definitive interpretation of net health benefit for the intended refractory population.

Coverage for posterior nasal nerve ablation (cryo/RF)

Covered when the following clinical and documentation criteria are satisfied

Clinical selection and evidence: Patient has chronic rhinitis refractory to medical management and posterior nasal nerve ablation (cryo or radiofrequency) is being considered; professional society statements support use as an option for medically-refractory patients.

International and specialty society statements (AAAI, AAO, ARS) describe these procedures as an option for medically-refractory patients but evidence quality is limited.

Documentation of refractory status: Medical record documents prior adequate medical therapy and failure to achieve adequate symptom control (examples used in studies: ≥4 weeks of intranasal steroid therapy or failure of medical therapy for ≥3 months), with baseline symptom assessment (eg, rTNSS) and duration of symptoms.document prior medical therapy and baseline rTNSS

Prior authorization, when required, should verify these elements; absence of documentation may preclude coverage.

Procedural modality limited to cryo or RF:

Laser ablation for chronic rhinitis is considered investigational. The document notes that there are no FDA‑cleared laser devices for treatment of chronic rhinitis and that the available evidence consists of a single nonrandomized, single‑arm study with short follow‑up and methodological limitations, preventing determination of improved net health outcomes.

Clinical trial reports and nonrandomized studies identified several exclusion conditions commonly used in study protocols: clinically significant nasal or sinus anatomy that limits visualization or access to the posterior nasal cavity or to accommodate the device; active or chronic nasal/sinus infection; septal perforation or prior surgery that significantly alters posterior nasal cavity anatomy; pregnancy; nasopharyngeal malignancy; rhinitis medicamentosa; coagulopathy or anticoagulant therapy; and other systemic conditions that could confound outcomes.

The excerpt does not list additional explicit exclusions beyond those used in individual studies; the principal applicability concern described is the absence of evidence that device effects generalize to patients who do not have documented failure of medical management.

Some procedural modalities (notably laser ablation) are supported only by single‑arm, nonrandomized studies. These designs lack a concurrent comparator and are open‑label, which introduces bias and limits ability to attribute observed symptom improvements to the intervention rather than placebo effect or natural history.

Overall, the evidence is insufficient to conclude that cryoablation, radiofrequency ablation, or laser ablation improve net health outcomes. Although randomized and nonrandomized studies reported symptom improvements, methodological limitations — including unclear refractory status of RCT participants, single‑arm designs, short follow‑up, and high loss to follow‑up in some studies — preclude definitive conclusions.

The randomized trials demonstrating statistical benefit versus sham did not clearly require or document that enrolled participants were refractory to medical management. Because the intended use is for patients who have failed medical therapy, this lack of explicit refractory‑to‑medical‑management enrollment criteria limits the applicability of RCT results to the target population.

The RCTs summarized in the document did not consistently enroll or document participants as refractory to prior medical management. The review highlights that many trials either did not require documented failure of medical therapy or did not report criteria clearly, creating uncertainty about whether the trial populations match the intended refractory patient group.

Evidence for laser ablation is limited to a single nonrandomized, single‑arm study (Krespi et al., 2020) with a 3‑month follow‑up. Although symptom scores improved in that study, the open‑label, uncontrolled design and the lack of a defined, reported criterion for refractory status limit confidence in attributing benefit to the procedure.

Procedure and Billing Codes

Codes table referencedmixed

No codes listed

Procedure CPT/HCPCS codesmixed

31242	Nasal/sinus endoscopy, surgical; with destruction by radiofrequency ablation, posterior nasal nerve.
31243	Nasal/sinus endoscopy, surgical; with destruction by cryoablation, posterior nasal nerve.
30999	Unlisted procedure, nose.
31299	Unlisted procedure, accessory sinuses.
No code(s)	HCPCS: No specific HCPCS code listed.

Symptoms timing — duration and timing references for chronic rhinitis and outcomes

Outcome measurement timingPrimary symptom measures (rTNSS) and other patient-reported outcomes in studies were timed at least 6 months or longer for outcome assessment.

Diagnosis timing vs outcome timingChronic rhinitis diagnosis is commonly defined as symptoms lasting >3 months, while study outcome timing for efficacy is typically ≥6 months.

Clinical follow-up reportedRandomized and nonrandomized studies reported outcomes at multiple time points (30 days, 3 months, 6 months, 12 months, and longer) although primary timing guidance cites ≥6 months.

rTNSS — threshold score used in studies (e.g., score ≥6)

rTNSS inclusion threshold used in trialsTotal rTNSS score ≥6 was used as an inclusion threshold in several studies.

Prior Authorization, Documentation, and Billing Guidance

Prior Authorization

Prior approval / benefit verification

Prior approval/benefit verification: Although the policy lists prior approval as Not applicable, providers should verify member benefits and confirm whether prior authorization is required by the payer before scheduling procedures. Benefit coverage and any plan-specific prior authorization rules can vary; obtain verification for the specific member and plan.

Verify member eligibility and benefits for procedures targeting the posterior nasal nerve prior to service
Confirm whether the member’s plan requires prior authorization for CPT 31242, 31243 or unlisted codes 30999/31299

Prior Authorization

Prior authorization required to confirm refractory status

Prior authorization requirement to confirm refractory status: Prior authorization may be required to document that an adult patient has chronic rhinitis refractory to adequate medical management. When prior auth is requested, the provider should demonstrate that the patient meets the clinical population described in the policy (adult ≥18 years with chronic allergic or nonallergic rhinitis refractory to medical therapy).

Confirm patient is an adult (≥18 years) with chronic rhinitis (symptoms typically ≥3 months)

Clinical Context and Evidence Overview

Chronic rhinitis encompasses allergic, nonallergic, and mixed forms and commonly responds to pharmacotherapy. The background notes that approximately 10–22% of patients have persistent symptoms despite medical therapy. For patients with symptoms that persist after adequate medical management, procedural disruption of the posterior nasal nerve (via cryoablation, radiofrequency, or in some reports laser) has been developed to reduce rhinorrhea and other nasal symptoms.

Key Definitions and Terms

Chronic rhinitis — definition and duration

Core definitionRhinorrhea with or without nasal congestion persisting despite medical therapy, usually lasting longer than 3 months.

Population ageRelevant population in studies and policy context: adults aged ≥18 years.

Included formsIncludes allergic, nonallergic, and mixed forms of rhinitis.

Refractory chronic rhinitis — definition and examples of adequate medical therapy thresholds

Definition of refractory chronic rhinitisChronic rhinitis not improving after adequate medical therapy; examples in studies include inadequate response after ≥4 weeks of intranasal steroid use or failure of medical therapy for ≥3 months.

Examples of adequate medical therapy thresholdsStudy examples: ≥4 weeks of intranasal steroids or ≥3 months of medical therapy before classifying as refractory.

Policy Summary

Payerblue cross blue shield - south dakota

PolicyCryoablation, Radiofrequency Ablation and Laser Ablation for Treatment of Chronic Rhinitis

Policy CodePolicy 07.01.86

Change TypePolicy renewal

Effective Date

Next Review Date

Key ActionVerify and document that the adult patient has chronic rhinitis refractory to adequate medical therapy before requesting coverage or prior authorization.

SourceLink

On This Page

Posterior nasal nerve ablation by cryoablation or radiofrequency may be considered when above clinical and documentation criteria are met; laser ablation remains investigational due to lack of FDA-cleared devices and limited evidence.

Laser ablation evidence is limited to single-arm study and no FDA-cleared laser devices for this indication.

rTNSS componentsrTNSS sums 4 symptom scores (rhinorrhea, congestion, itching, sneezing) each 0–3 for a maximum of 12.

Responder threshold referenced for contextStudies used percentage improvements in rTNSS (e.g., ≥30% improvement) as responder outcomes alongside baseline thresholds.

Provide prior authorization evidence that medical therapy was attempted and failed prior to device/procedure consideration

Documentation Required

Prior authorization: document refractory status

Document refractory status during prior authorization: When submitting a prior authorization request, include documentation of the patient’s refractory status and prior medical management. Lack of documentation that the patient was refractory to adequate medical therapy is a common reason a request or claim may be denied.

Specify the duration of symptoms and duration of prior medical therapies (e.g., ≥3 months or as applicable)
Include baseline symptom scores (for example, baseline rTNSS or TNSS) if available
List specific medications/trials and responses (intranasal steroids, intranasal anticholinergics, oral/intranasal antihistamines, other therapies)

Denial Risk

Investigational stance may trigger denial

Investigational stance may trigger denial: Cryoablation, radiofrequency ablation, and laser ablation for chronic rhinitis are considered investigational by this policy. Requests for these procedures for indications covered as investigational may be subject to denial. If submitted, provide comprehensive documentation showing medical necessity and prior conservative management.

Expect denials for indications that align with the policy’s investigational determinations
When pursuing approval despite investigational status, include thorough clinical justification and prior therapy documentation

Documentation Required

Documentation of prior medical management

Documentation of prior medical management: Providers should document trials of appropriate stepwise medical therapy prior to consideration of device-based or ablative procedures. Documentation should show inadequate symptom control despite adequate use of medical treatments.

Document trial(s) and duration of intranasal corticosteroids (typical minimums in studies ranged from 4 weeks to 3 months)
Document trial(s) of intranasal anticholinergic sprays (e.g., ipratropium) and antihistamines when indicated
Include notes on adherence, dosing, and objective or patient-reported response to therapies

Denial Risk

Refractory-to-medical-management documentation risk

Refractory-to-medical-management documentation risk: Many studies and some trial reports did not clearly define or document refractory status, creating adjudication risk for prior authorization and claims. Absence of clear refractory documentation may limit the ability to approve or defend a claim.

Recognize that ambiguous or absent documentation of prior therapy and refractory status increases the likelihood of denial or request for more information
If study definitions differ, align documentation to the payer’s expectations (explicit durations, failed agents, and baseline symptom severity)

Documentation Required

Documentation of prior medical management needed

Documentation of prior medical management needed: To facilitate adjudication, include explicit statements of prior medical therapy failures and objective symptom baselines used in study definitions when available. This helps reviewers determine whether the patient matches the intended refractory population.

State exact therapies tried, duration, and patient response (e.g., intranasal steroid x12 weeks with inadequate symptom control)
Provide baseline symptom scores (rTNSS/TNSS) and relevant subscores if recorded

Documentation Required

Required clinical documentation

Required clinical documentation: At minimum, prior authorization and claims should include a clinical diagnosis of chronic rhinitis, documentation that symptoms have persisted despite adequate medical therapy, duration of symptoms, a list of prior therapies with durations and responses, and baseline symptom severity measures where available.

Clinical diagnosis (allergic, nonallergic, or mixed chronic rhinitis) and symptom duration (typically ≥3 months)
List of prior medical therapies with dates, doses, adherence, and documented inadequate response
Baseline symptom scoring (rTNSS, TNSS or equivalent) and any objective findings supporting diagnosis

Documentation Required

Refractory status and symptom baseline documentation

Refractory status and symptom baseline documentation: When possible, include baseline validated symptom scores (for example, rTNSS or TNSS) and the duration of symptoms used to establish refractory status. Many studies used thresholds (e.g., rTNSS ≥6) or subscores to define eligibility; reporting these helps reviewers assess comparability.

Provide baseline total and subscore values (e.g., rTNSS total and rhinorrhea/congestion subscores) if available
Document the time period over which medical therapies were tried and judged inadequate

Documentation Required

Document prior medical therapy

Document prior medical therapy: Explicitly list medications and nonpharmacologic measures attempted, with dates and outcomes. Common therapies to document include intranasal corticosteroids, intranasal anticholinergics (e.g., ipratropium), oral/intranasal antihistamines, and other relevant interventions.

Name each medication or intervention, start and stop dates, dosing, and documented effectiveness or intolerance
Note any contraindications or reasons certain therapies were not tried

Step Therapy

Medical management prerequisite / Step therapy expectation

Medical management prerequisite and step therapy expectation: The policy and available evidence expect an antecedent trial of adequate medical therapy before considering ablative procedures. Providers should follow a stepwise approach and document failure of conservative medical therapy prior to device-based interventions.

Follow and document stepwise trials of intranasal steroids, intranasal anticholinergics, and antihistamines as clinically indicated
Document duration and adequacy of each trial (examples: intranasal steroid at therapeutic dose for ≥4 weeks to ≥3 months depending on clinical judgement)

Step Therapy

Stepwise medical therapy prior to device therapy

Stepwise medical therapy prior to device therapy: Before device-based posterior nasal nerve ablation is pursued, document failure of stepwise medical therapy and include this information in any prior authorization submission. Reviewers will look for evidence that conservative therapies were optimized and ineffective.

Ensure documentation shows sequential or concurrent trials of appropriate therapies and reasons for proceeding to procedural therapy
Include patient preference discussion and rationale for choosing procedural intervention when applicable

Documentation expectationTrials and prior-authorization guidance expect documentation of prior medical management and failure to achieve adequate symptom control.

Chronic rhinitis — brief definition (rhinorrhea with/without congestion >3 months)

Brief clinical definitionRhinorrhea with or without nasal congestion despite medical therapy lasting longer than 3 months.

ContextUsed to distinguish chronic from acute or intermittent rhinitis in study eligibility and documentation requirements.

Allergic rhinitis — IgE-mediated response definition and common symptoms

Pathophysiology definitionAllergic rhinitis is an IgE-mediated inflammatory response of the nasal mucous membranes after exposure to inhaled allergens.

Common symptomsSymptoms include rhinorrhea (anterior or postnasal drip), nasal congestion, nasal itching, and sneezing.

Pattern of symptomsAllergic rhinitis can be seasonal or perennial and may be intermittent or persistent.

Cryoablation (ClariFix) — device and mechanism summary

Device name and exampleClariFix system (cryoablation) uses nitrous oxide to freeze tissue in the posterior nasal nerve region.

MechanismFreezing causes nerve injury in posterior nasal nerve branches, reducing parasympathetic-driven secretions and blood flow to nasal mucosa.

Procedure settingCan be performed under local anesthesia and via endoscopic guidance in an office setting.

Radiofrequency ablation (RhinAer) — device and mechanism summary

Device name and exampleRhinAer Stylus (radiofrequency ablation) is a handheld device delivering radiofrequency energy to the posterior nasal nerve region.

Mechanism and parametersDelivers radiofrequency energy at approximately 60°C to ablate posterior nasal nerve branches, intended to disrupt efferent parasympathetic signaling.

Procedure settingDesigned for use under local anesthesia in an office setting per study descriptions.

Laser ablation — note on lack of FDA-cleared devices

Regulatory status noteThere are currently no laser ablation devices with FDA clearance for treatment of chronic rhinitis.

Evidence noteLaser ablation evidence is limited to single-arm, nonrandomized studies with short follow-up and undefined refractory criteria.

Policy implicationLack of FDA-cleared laser devices contributes to consideration of laser ablation as investigational for chronic rhinitis.

rTNSS — reflective Total Nasal Symptom Score explained

What rTNSS isReflective Total Nasal Symptom Score (rTNSS) is the sum of 4 patient-assessed symptoms: rhinorrhea, nasal congestion, nasal itching, and sneezing, each scored 0–3 for a maximum of 12.

Use in trialsrTNSS is a primary patient-reported symptom outcome used in randomized and nonrandomized studies of ablative interventions.

MCID contextA minimally clinically important difference has not been universally established; a 30% change from baseline has been proposed as meaningful in studies.

Responder (≥30% improvement) — definition used in trials

Responder definition used in trialsResponder defined as achieving ≥30% improvement in rTNSS from baseline (proportion of patients meeting this threshold reported in multiple studies).

Timepoints reportedResponder rates were reported at multiple follow-up points (eg, 3 months, 6 months, 12 months) depending on the study.

Context of useResponder (≥30%) used alongside mean rTNSS change to characterize clinically relevant symptom improvement in trials.

Posterior nasal nerve ablation — procedural definition (cryo/RF/laser)

Procedural definitionPosterior nasal nerve ablation is the procedural disruption or destruction of posterior nasal nerve branches (via cryoablation, radiofrequency ablation, or in some reports laser) to reduce rhinorrhea and other nasal symptoms.

Intended physiologic effectAblation interrupts efferent parasympathetic stimulation of the nasal mucosa, leading to reduced submucosal gland secretions and vascular hyperreactivity.

Typical approachesApproaches include cryotherapy (nitrous-oxide freezing), radiofrequency heating (~60°C), and laser energy in non–FDA-cleared reports; procedures are performed endoscopically, often in office under local anesthesia.